Overexpression of SerpinB9 in non-seminomatous germ cell tumors

被引：0

作者：

Anami, Toshiki ^{[1
,2
]}

Ibe, Yuki ^{[1
,2
]}

Li, Lianbo ^{[1
,3
]}

Komohara, Yoshihiro ^{[1
,4
]}

Hirao, Hiroki ^{[1
,3
]}

Harada, Mamoru ^{[5
]}

Yano, Hiromu ^{[1
]}

Fujiwara, Yukio ^{[1
]}

Motoshima, Takanobu ^{[2
]}

Yatsuda, Junji ^{[2
]}

Hibi, Taizo ^{[3
]}

Kamba, Tomomi ^{[2
]}

机构：

[1] Kumamoto Univ, Grad Sch Med Sci, Dept Cell Pathol, 1-1-1 Honjo,Kumamoto Chuo Ku, Kumamoto 8608556, Japan

[2] Kumamoto Univ, Grad Sch Med Sci, Dept Urol, Kumamoto, Japan

[3] Kumamoto Univ, Grad Sch Med Sci, Dept Pediat Surg & Transplantat, Kumamoto, Japan

[4] Kumamoto Univ, Ctr Metab Regulat Hlth Aging, Kumamoto, Japan

[5] Shimane Univ, Dept Immunol, Fac Med, Shimane, Japan

来源：

MEDICAL MOLECULAR MORPHOLOGY | 2024年 / 57卷 / 01期

基金：

日本学术振兴会;

关键词：

SerpinB9; Seminoma; Embryonal carcinoma; Yolk sac tumor; HLA; CD204-POSITIVE MACROPHAGES; TARGETS;

D O I：

10.1007/s00795-023-00374-9

中图分类号：

Q [生物科学];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Serpinb9 is an inhibitor of granzyme B and is potentially involved in the immune escape of tumor cells. In the present study, bioinformatics analysis using open databases suggested that SerpinB9 is overexpressed in testicular embryonal carcinoma. Immunohistological analysis was performed on 28 cases of testicular germ cell tumors to investigate the relationship between SerpinB9 expression in testicular germ cell tumors and the tumor immune environment. SerpinB9 was significantly upregulated in the non-seminoma group and inversely correlated with the number of tumor-infiltrating CD8-positive cells. In addition, yolk sac tumors were characterized by the loss of human leukocyte antigen-class I expression. These findings suggest that SerpinB9 contributes to the immune escape of testicular germ cell tumors. Targeting therapy for SerpinB9 might therefore be useful in immunotherapy for testicular germ cell tumors resistant to immune checkpoint inhibitors.

引用

页码：45 / 58

页数：14

共 19 条

[1] Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: Results of the German Testicular Cancer Study Group Trial
Albers, P
Siener, R
Kliesch, S
Weissbach, L
Krege, S
Sparwasser, C
Schulze, H
Heidenreich, A
de Riese, W
Loy, V
Bierhoff, E
Wittekind, C
Fimmers, R
Hartmann, M
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (08) : 1505 - 1512
[2] The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma
Cathomas, Richard
Lorch, Anja
Bruins, Harman M.
Comperat, Eva M.
Cowan, Nigel C.
Efstathiou, Jason A.
Fietkau, Rainer
Gakis, Georgios
Hernandez, Virginia
Espinos, Estefania Linares
Neuzillet, Yann
Ribal, Maria J.
Rouanne, Matthieu
Thalmann, George N.
van der Heijden, Antoine G.
Veskimae, Erik
Witjes, J. Alfred
Milowsky, Matthew I.
[J]. EUROPEAN UROLOGY, 2022, 81 (01) : 95 - 103
[3] Risk factors for relapse in patients with clinical stage I testicular nonseminomatous germ cell tumors
Dong, Pei
Liu, Zhuo-Wei
Li, Xiang-Dong
Li, Yong-Hong
Yao, Kai
Wu, Song
Qin, Zi-Ke
Han, Hui
Zhou, Fang-Jian
[J]. MEDICAL ONCOLOGY, 2013, 30 (01)
[4] Macrophage and monocyte subsets as new therapeutic targets in cancer immunotherapy
Fendl, B.
Berghoff, A. S.
Preusser, M.
Maier, B.
[J]. ESMO OPEN, 2023, 8 (01)
[5] The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition
Hegde, Priti S.
Karanikas, Vaios
Evers, Stefan
[J]. CLINICAL CANCER RESEARCH, 2016, 22 (08) : 1865 - 1874
[6] Prognostic Impact of CD204-Positive Macrophages in Lung Squamous Cell Carcinoma Possible Contribution of Cd204-Positive Macrophages to the Tumor-Promoting Microenvironment
Hirayama, Shunki
Ishii, Genichiro
Nagai, Kanji
Ono, Shotaro
Kojima, Motohiro
Yamauchi, Chisako
Aokage, Keiju
Hishida, Tomoyuki
Yoshida, Junji
Suzuki, Kenji
Ochiai, Atsushi
[J]. JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (12) : 1790 - 1797
[7] SERPINB9 is commonly amplified and high expression in cancer cells correlates with poor immune checkpoint blockade response
Ibanez-Molero, Sofia
van Vliet, Alex
Pozniak, Joanna
Hummelink, Karlijn
Terry, Alexandra M.
Monkhorst, Kim
Sanders, Joyce
Hofland, Ingrid
Landeloos, Ewout
Van Herck, Yannick
Bechter, Oliver
Kuilman, Thomas
Zhong, Weiwei
Marine, Jean-Christophe
Wessels, Lodewyk
Peeper, Daniel S.
[J]. ONCOIMMUNOLOGY, 2022, 11 (01):
[8] Direct Tumor Killing and Immunotherapy through Anti-SerpinB9 Therapy
Jiang, Liwei
Wang, Yi-Jun
Zhao, Jing
Uehara, Mayuko
Hou, Qingming
Kasinath, Vivek
Ichimura, Takaharu
Banouni, Naima
Dai, Li
Li, Xiaofei
Greiner, Dale L.
Shultz, Leonard D.
Zhang, Xiaolong
Sun, Zhen-Yu Jim
Curtin, Ian
Vangos, Nicholas E.
Yeoh, Zoe C.
Geffken, Ezekiel A.
Seo, Hyuk-Soo
Liu, Ze-Xian
Heffron, Gregory J.
Shah, Khalid
Dhe-Paganon, Sirano
Abdi, Reza
[J]. CELL, 2020, 183 (05) : 1219 - +
[9] THE EXPRESSION OF HLA CLASS-I ANTIGENS IN GERM-CELL TESTICULAR CANCER
KLEIN, B
KLEIN, T
KONICHEZKY, M
NYSKA, A
LIVINI, E
LEVINE, I
ZAMIR, R
KOOPERMAN, O
LURIE, H
[J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1990, 93 (02) : 202 - 207
[10] Involvement of protumor macrophages in breast cancer progression and characterization of macrophage phenotypes
Komohara, Yoshihiro
Kurotaki, Daisuke
Tsukamoto, Hirotake
Miyasato, Yuko
Yano, Hiromu
Pan, Cheng
Yamamoto, Yutaka
Fujiwara, Yukio
[J]. CANCER SCIENCE, 2023, 114 (06) : 2220 - 2229

← 1 2 →